Monitoring Agency Report for the quarter ended December 31, 2025 for the Preferential Allotment made on July 19, 2024
FCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fineotex Chemical has filed the ICRA Monitoring Agency Report for the quarter ended December 31, 2025, covering proceeds from its July 2024 preferential issue of equity shares and convertible warrants. The total issue size was Rs. 218.11 crores, but only Rs. 136.32 crores was actually received (25% warrant money credited). All received funds have been fully utilized, with Rs. 124.48 crores deployed toward business expansion, Rs. 10.27 crores for working capital, and Rs. 1.56 crores for general corporate purposes. During Q3 FY2026 alone, the company spent Rs. 94.28 crores on expansion, showing a sharp pickup in capex deployment. ICRA confirmed no deviation from stated objects, no unfavorable events, and all projects remain on schedule for completion by September 2030.
Routine compliance filing with no red flags — ICRA confirmed funds are being used as promised. The heavy Rs. 94+ crore expansion spend in a single quarter signals aggressive capacity/capex buildout, which is a positive growth signal for shareholders. Limited immediate stock impact expected as this is a procedural update.